BG103754A - Заместени 4-арилметилен-2-имино-2,3-дихидротиазоли, техни производни и използването им във фармацията - Google Patents

Заместени 4-арилметилен-2-имино-2,3-дихидротиазоли, техни производни и използването им във фармацията Download PDF

Info

Publication number: BG103754A
Authority: BG; Bulgaria
Prior art keywords: dihydrothiazole; cyclobutyl; carbon atoms; dichlorophenyl; optionally substituted
Prior art date: 1997-03-15

Application number

BG103754A

Other languages

Bulgarian (bg)

English (en)

Inventor

Sharon Cheetham

Frank Kerrigan

Colin Jones

Original Assignee

Knoll Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-15

Filing date

1999-09-24

Publication date

2000-06-30

1999-09-24 Application filed by Knoll Gmbh filed Critical Knoll Gmbh

2000-06-30 Publication of BG103754A publication Critical patent/BG103754A/bg

Links

150000001875 compounds Chemical class 0.000 claims abstract description 159
239000000203 mixture Substances 0.000 claims abstract description 118
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 97
-1 benzo(b)thiophenyl Chemical group 0.000 claims abstract description 77
125000000217 alkyl group Chemical group 0.000 claims abstract description 47
125000003118 aryl group Chemical group 0.000 claims abstract description 23
238000000034 method Methods 0.000 claims abstract description 23
125000004429 atom Chemical group 0.000 claims abstract description 22
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 22
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 18
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 16
125000001624 naphthyl group Chemical group 0.000 claims abstract description 13
238000002360 preparation method Methods 0.000 claims abstract description 12
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 10
125000002947 alkylene group Chemical group 0.000 claims abstract description 9
208000012902 Nervous system disease Diseases 0.000 claims abstract description 8
208000025966 Neurological disease Diseases 0.000 claims abstract description 8
208000020401 Depressive disease Diseases 0.000 claims abstract description 7
125000003342 alkenyl group Chemical group 0.000 claims abstract description 6
125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 6
125000004446 heteroarylalkyl group Chemical group 0.000 claims abstract description 6
125000005002 aryl methyl group Chemical group 0.000 claims abstract description 5
125000004981 cycloalkylmethyl group Chemical group 0.000 claims abstract description 5
125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 4
125000005843 halogen group Chemical group 0.000 claims description 61
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 39
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 37
150000002367 halogens Chemical class 0.000 claims description 36
229910052736 halogen Inorganic materials 0.000 claims description 35
125000001424 substituent group Chemical group 0.000 claims description 25
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 22
125000003545 alkoxy group Chemical group 0.000 claims description 21
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 17
125000004414 alkyl thio group Chemical group 0.000 claims description 17
229910052739 hydrogen Inorganic materials 0.000 claims description 14
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 14
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 claims description 10
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
206010010904 Convulsion Diseases 0.000 claims description 7
208000027089 Parkinsonian disease Diseases 0.000 claims description 7
206010034010 Parkinsonism Diseases 0.000 claims description 7
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 6
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
239000004090 neuroprotective agent Substances 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 5
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 4
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 3
XHBLOTICYAEWOZ-UHFFFAOYSA-N 3-[1-(3,4-dichlorophenyl)cyclobutyl]-5-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound N12C(C)CN=C2SC=C1C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 XHBLOTICYAEWOZ-UHFFFAOYSA-N 0.000 claims description 2
KILNDGCEQXIIJU-UHFFFAOYSA-N 3-[1-(3-fluorophenyl)cyclobutyl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound FC1=CC=CC(C2(CCC2)C=2N3CCN=C3SC=2)=C1 KILNDGCEQXIIJU-UHFFFAOYSA-N 0.000 claims description 2
OGIHLNAIOATGSR-UHFFFAOYSA-N 3-[1-(4-methylsulfanylphenyl)cyclobutyl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC(SC)=CC=C1C1(C=2N3CCN=C3SC=2)CCC1 OGIHLNAIOATGSR-UHFFFAOYSA-N 0.000 claims description 2
PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 2
YABJLYQVPIPDMA-UHFFFAOYSA-N n,3-bis(4-ethoxyphenyl)-4-(1-naphthalen-2-ylcyclobutyl)-1,3-thiazol-2-imine Chemical compound C1=CC(OCC)=CC=C1N=C1N(C=2C=CC(OCC)=CC=2)C(C2(CCC2)C=2C=C3C=CC=CC3=CC=2)=CS1 YABJLYQVPIPDMA-UHFFFAOYSA-N 0.000 claims description 2
CONIZJYXKKRKSS-UHFFFAOYSA-N n,3-dicyclopentyl-4-(1-naphthalen-2-ylcyclobutyl)-1,3-thiazol-2-imine Chemical compound C1CCC1(C=1C=C2C=CC=CC2=CC=1)C(N1C2CCCC2)=CSC1=NC1CCCC1 CONIZJYXKKRKSS-UHFFFAOYSA-N 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
KNEDPNIYOJPCTK-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis(2-phenylethyl)-1,3-thiazol-2-imine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C=2N(C(=NCCC=3C=CC=CC=3)SC=2)CCC=2C=CC=CC=2)CCC1 KNEDPNIYOJPCTK-UHFFFAOYSA-N 0.000 claims 1
OIQFPGHUVXLXCX-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-dipropyl-1,3-thiazol-2-imine Chemical compound CCCN1C(=NCCC)SC=C1C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 OIQFPGHUVXLXCX-UHFFFAOYSA-N 0.000 claims 1
XPOSGVNDXZZZCC-UHFFFAOYSA-N 4-[1-(4-chlorophenyl)cyclopentyl]-n,3-bis[2-(3,4-dimethoxyphenyl)ethyl]-1,3-thiazol-2-imine Chemical compound C1=C(OC)C(OC)=CC=C1CCN=C1N(CCC=2C=C(OC)C(OC)=CC=2)C(C2(CCCC2)C=2C=CC(Cl)=CC=2)=CS1 XPOSGVNDXZZZCC-UHFFFAOYSA-N 0.000 claims 1
DINXQSYNWHLKSS-UHFFFAOYSA-N n,3-bis[2-(3,4-dimethoxyphenyl)ethyl]-4-(1-naphthalen-2-ylcyclobutyl)-1,3-thiazol-2-imine Chemical compound C1=C(OC)C(OC)=CC=C1CCN=C1N(CCC=2C=C(OC)C(OC)=CC=2)C(C2(CCC2)C=2C=C3C=CC=CC3=CC=2)=CS1 DINXQSYNWHLKSS-UHFFFAOYSA-N 0.000 claims 1
OKQDCONLUFMRRB-UHFFFAOYSA-N n,3-dibutyl-4-[2-(3,4-dichlorophenyl)propan-2-yl]-1,3-thiazol-2-imine Chemical compound CCCCN1C(=NCCCC)SC=C1C(C)(C)C1=CC=C(Cl)C(Cl)=C1 OKQDCONLUFMRRB-UHFFFAOYSA-N 0.000 claims 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
125000000547 substituted alkyl group Chemical group 0.000 abstract description 5
208000019901 Anxiety disease Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 126
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 97
238000004128 high performance liquid chromatography Methods 0.000 description 70
239000000243 solution Substances 0.000 description 65
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 54
239000002904 solvent Substances 0.000 description 51
239000007787 solid Substances 0.000 description 47
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 36
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 36
238000003756 stirring Methods 0.000 description 32
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
238000010992 reflux Methods 0.000 description 25
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
239000003921 oil Substances 0.000 description 22
235000019198 oils Nutrition 0.000 description 22
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
230000027455 binding Effects 0.000 description 21
239000000047 product Substances 0.000 description 20
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
229960003638 dopamine Drugs 0.000 description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
239000008187 granular material Substances 0.000 description 16
239000003446 ligand Substances 0.000 description 16
238000012360 testing method Methods 0.000 description 16
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
239000000284 extract Substances 0.000 description 14
238000001914 filtration Methods 0.000 description 14
229960002748 norepinephrine Drugs 0.000 description 14
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 14
239000003826 tablet Substances 0.000 description 14
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 13
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 13
229910052794 bromium Inorganic materials 0.000 description 13
229920006395 saturated elastomer Polymers 0.000 description 13
239000007788 liquid Substances 0.000 description 12
229910052943 magnesium sulfate Inorganic materials 0.000 description 12
235000019341 magnesium sulphate Nutrition 0.000 description 12
239000012299 nitrogen atmosphere Substances 0.000 description 12
230000009870 specific binding Effects 0.000 description 12
239000000725 suspension Substances 0.000 description 12
238000009835 boiling Methods 0.000 description 11
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
PDQAZBWRQCGBEV-UHFFFAOYSA-N Ethylenethiourea Chemical compound S=C1NCCN1 PDQAZBWRQCGBEV-UHFFFAOYSA-N 0.000 description 10
238000000746 purification Methods 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
239000012839 Krebs-Henseleit buffer Substances 0.000 description 9
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
239000007983 Tris buffer Substances 0.000 description 9
239000002775 capsule Substances 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
235000017557 sodium bicarbonate Nutrition 0.000 description 9
229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
230000009871 nonspecific binding Effects 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
NWABWFPZIMWXHT-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole;hydrobromide Chemical compound Br.C1NC=CS1 NWABWFPZIMWXHT-UHFFFAOYSA-N 0.000 description 7
229930006000 Sucrose Natural products 0.000 description 7
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
210000005013 brain tissue Anatomy 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
239000003208 petroleum Substances 0.000 description 7
239000000377 silicon dioxide Substances 0.000 description 7
239000005720 sucrose Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 6
239000013543 active substance Substances 0.000 description 6
239000003480 eluent Substances 0.000 description 6
238000003818 flash chromatography Methods 0.000 description 6
239000011777 magnesium Substances 0.000 description 6
229910052749 magnesium Inorganic materials 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000012528 membrane Substances 0.000 description 6
239000002699 waste material Substances 0.000 description 6
DDGHBOLOCQWPKE-UHFFFAOYSA-N 1,3-thiazole;hydrobromide Chemical compound [Br-].C1=CSC=[NH+]1 DDGHBOLOCQWPKE-UHFFFAOYSA-N 0.000 description 5
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
238000009472 formulation Methods 0.000 description 5
VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 5
238000001819 mass spectrum Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
229910052938 sodium sulfate Inorganic materials 0.000 description 5
235000011152 sodium sulphate Nutrition 0.000 description 5
239000000829 suppository Substances 0.000 description 5
CTKUIZGFDSJHPY-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)cyclobutane-1-carbonitrile Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C#N)CCC1 CTKUIZGFDSJHPY-UHFFFAOYSA-N 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
GDLAAGCDLYXWCK-UHFFFAOYSA-N 2-bromo-1-[1-(3,4-dichlorophenyl)cyclobutyl]ethanone Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C(=O)CBr)CCC1 GDLAAGCDLYXWCK-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
125000001246 bromo group Chemical group Br* 0.000 description 4
125000001309 chloro group Chemical group Cl* 0.000 description 4
230000001054 cortical effect Effects 0.000 description 4
206010015037 epilepsy Diseases 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000003701 inert diluent Substances 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000001103 potassium chloride Substances 0.000 description 4
235000011164 potassium chloride Nutrition 0.000 description 4
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
238000005303 weighing Methods 0.000 description 4
125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 3
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
229940081734 cellulose acetate phthalate Drugs 0.000 description 3
238000000576 coating method Methods 0.000 description 3
229940125773 compound 10 Drugs 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
125000003107 substituted aryl group Chemical group 0.000 description 3
210000003568 synaptosome Anatomy 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 description 3
238000003828 vacuum filtration Methods 0.000 description 3
238000003260 vortexing Methods 0.000 description 3
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
NVHNGVXBCWYLFA-UHFFFAOYSA-N 1,3-diazinane-2-thione Chemical compound S=C1NCCCN1 NVHNGVXBCWYLFA-UHFFFAOYSA-N 0.000 description 2
VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 2
ULJNHRLENREBDQ-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)cyclobutane-1-carbonitrile Chemical compound C=1C2=CC=CC=C2SC=1C1(C#N)CCC1 ULJNHRLENREBDQ-UHFFFAOYSA-N 0.000 description 2
IGXORXGLKLJKAQ-UHFFFAOYSA-N 1-(1-naphthalen-2-ylcyclobutyl)ethanone Chemical compound C=1C=C2C=CC=CC2=CC=1C1(C(=O)C)CCC1 IGXORXGLKLJKAQ-UHFFFAOYSA-N 0.000 description 2
LIPSDVBHSHEGGB-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)cyclopentane-1-carbonitrile Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C#N)CCCC1 LIPSDVBHSHEGGB-UHFFFAOYSA-N 0.000 description 2
MWWHAQHPPPSZLO-UHFFFAOYSA-N 1-[1-(1-benzothiophen-2-yl)cyclobutyl]-2-bromoethanone Chemical compound C=1C2=CC=CC=C2SC=1C1(C(=O)CBr)CCC1 MWWHAQHPPPSZLO-UHFFFAOYSA-N 0.000 description 2
YKZRDIFPACHYNK-UHFFFAOYSA-N 1-[1-(1-benzothiophen-2-yl)cyclobutyl]ethanone Chemical compound C=1C2=CC=CC=C2SC=1C1(C(=O)C)CCC1 YKZRDIFPACHYNK-UHFFFAOYSA-N 0.000 description 2
AXKJZNZBVAZMGS-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)cyclobutyl]-2-(4,5-dihydro-1h-imidazol-2-ylsulfanyl)ethanone;hydrobromide Chemical compound Br.C1=C(Cl)C(Cl)=CC=C1C1(C(=O)CSC=2NCCN=2)CCC1 AXKJZNZBVAZMGS-UHFFFAOYSA-N 0.000 description 2
UJVBBKHBMOGCAJ-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)cyclobutyl]-2-phenylethanone Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C(=O)CC=2C=CC=CC=2)CCC1 UJVBBKHBMOGCAJ-UHFFFAOYSA-N 0.000 description 2
MDPJGCZTXIAMEF-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)cyclobutyl]ethanone Chemical compound C=1C=C(Cl)C(Cl)=CC=1C1(C(=O)C)CCC1 MDPJGCZTXIAMEF-UHFFFAOYSA-N 0.000 description 2
YNQPKAQOSTXSBN-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)cyclopentyl]ethanone Chemical compound C=1C=C(Cl)C(Cl)=CC=1C1(C(=O)C)CCCC1 YNQPKAQOSTXSBN-UHFFFAOYSA-N 0.000 description 2
XRUVUCBAYNAAPE-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-2-(4,5-dihydro-1h-imidazol-2-ylsulfanyl)ethanone;hydrobromide Chemical compound Br.C1=CC(Cl)=CC=C1C1(C(=O)CSC=2NCCN=2)CCC1 XRUVUCBAYNAAPE-UHFFFAOYSA-N 0.000 description 2
RAQPOZGWANIDQT-UHFFFAOYSA-N 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCN(CC1)CCN1CCOC(C=1C=CC=CC=1)C1=CC=CC=C1 RAQPOZGWANIDQT-UHFFFAOYSA-N 0.000 description 2
XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 2
YRQZPEHIUCAMMP-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)C1=CC=C(Cl)C(Cl)=C1 YRQZPEHIUCAMMP-UHFFFAOYSA-N 0.000 description 2
QWZNCAFWRZZJMA-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetonitrile Chemical compound ClC1=CC=C(CC#N)C=C1Cl QWZNCAFWRZZJMA-UHFFFAOYSA-N 0.000 description 2
DIQJGFRPYNOZTR-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-[1-(3,4-dichlorophenyl)cyclobutyl]ethanone Chemical compound C1=CC(Cl)=CC=C1CC(=O)C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 DIQJGFRPYNOZTR-UHFFFAOYSA-N 0.000 description 2
JHDSVVPTMIYVGV-UHFFFAOYSA-N 2-(chloromethyl)-1-benzothiophene Chemical compound C1=CC=C2SC(CCl)=CC2=C1 JHDSVVPTMIYVGV-UHFFFAOYSA-N 0.000 description 2
IIVOQEDEARAZTH-UHFFFAOYSA-N 2-bromo-1-(1-naphthalen-2-ylcyclobutyl)ethanone Chemical compound C=1C=C2C=CC=CC2=CC=1C1(C(=O)CBr)CCC1 IIVOQEDEARAZTH-UHFFFAOYSA-N 0.000 description 2
WUSBFILTANCWME-UHFFFAOYSA-N 2-bromo-1-[1-(3,4-dichlorophenyl)cyclobutyl]-2-phenylethanone Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C(=O)C(Br)C=2C=CC=CC=2)CCC1 WUSBFILTANCWME-UHFFFAOYSA-N 0.000 description 2
OOHUDHQIIVSNSH-UHFFFAOYSA-N 2-bromo-1-[1-(3,4-dichlorophenyl)cyclopentyl]ethanone Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C(=O)CBr)CCCC1 OOHUDHQIIVSNSH-UHFFFAOYSA-N 0.000 description 2
FGOIOSAWZPKWEC-UHFFFAOYSA-N 2-bromo-1-[1-(4-chlorophenyl)cyclobutyl]-3-phenylpropan-1-one Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)C(Br)CC=2C=CC=CC=2)CCC1 FGOIOSAWZPKWEC-UHFFFAOYSA-N 0.000 description 2
YPEWWCINWMJFRK-UHFFFAOYSA-N 2-bromo-1-[1-(4-chlorophenyl)cyclobutyl]ethanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)CBr)CCC1 YPEWWCINWMJFRK-UHFFFAOYSA-N 0.000 description 2
RKDIVOLNBXAMRH-UHFFFAOYSA-N 2-bromo-2-(4-chlorophenyl)-1-[1-(3,4-dichlorophenyl)cyclobutyl]ethanone Chemical compound C1=CC(Cl)=CC=C1C(Br)C(=O)C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 RKDIVOLNBXAMRH-UHFFFAOYSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
ITJNARMNRKSWTA-RLXJOQACSA-N 3-(2-methoxyphenoxy)-3-phenyl-n-(tritritiomethyl)propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC([3H])([3H])[3H])OC1=CC=CC=C1OC ITJNARMNRKSWTA-RLXJOQACSA-N 0.000 description 2
VAUTXHVUUUNKDG-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-3-methylbutan-2-one Chemical compound CC(=O)C(C)(C)C1=CC=C(Cl)C(Cl)=C1 VAUTXHVUUUNKDG-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
VFHWCZMTMRVBAN-UHFFFAOYSA-N acetaldehyde hydrobromide Chemical compound Br.CC=O VFHWCZMTMRVBAN-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
238000010533 azeotropic distillation Methods 0.000 description 2
HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
125000002541 furyl group Chemical group 0.000 description 2
239000007789 gas Substances 0.000 description 2
238000004817 gas chromatography Methods 0.000 description 2
239000005457 ice water Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
229960000299 mazindol Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000004570 mortar (masonry) Substances 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
239000013557 residual solvent Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000012453 solvate Substances 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
150000003557 thiazoles Chemical class 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
GNLJBJNONOOOQC-UHFFFAOYSA-N $l^{3}-carbane;magnesium Chemical compound [Mg]C GNLJBJNONOOOQC-UHFFFAOYSA-N 0.000 description 1
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
MYMALJRSNVUBAI-UHFFFAOYSA-N 1,3-thiazol-4-imine Chemical class N=C1CSC=N1 MYMALJRSNVUBAI-UHFFFAOYSA-N 0.000 description 1
VBXZSFNZVNDOPB-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrimidine Chemical compound C1CNC=NC1 VBXZSFNZVNDOPB-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
XQONXPWVIZZJIL-UHFFFAOYSA-N 1-(4-chlorophenyl)cyclobutane-1-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1(C#N)CCC1 XQONXPWVIZZJIL-UHFFFAOYSA-N 0.000 description 1
RHXSYYDYZJFWCS-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)cyclobutyl]-2-(1,4,5,6-tetrahydropyrimidin-2-ylsulfanyl)ethanone;hydrobromide Chemical compound Br.C1=C(Cl)C(Cl)=CC=C1C1(C(=O)CSC=2NCCCN=2)CCC1 RHXSYYDYZJFWCS-UHFFFAOYSA-N 0.000 description 1
AYMJNNBNRAYBNW-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)cyclobutyl]-4-methoxybutan-1-one Chemical compound C=1C=C(Cl)C(Cl)=CC=1C1(C(=O)CCCOC)CCC1 AYMJNNBNRAYBNW-UHFFFAOYSA-N 0.000 description 1
HCFLOJXLYONXDY-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)cyclobutyl]-4-methoxybutan-2-one Chemical compound C=1C=C(Cl)C(Cl)=CC=1C1(CC(=O)CCOC)CCC1 HCFLOJXLYONXDY-UHFFFAOYSA-N 0.000 description 1
WHKKSMPSUOZMJO-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-2-(1,4,5,6-tetrahydropyrimidin-2-ylsulfanyl)ethanone;hydrobromide Chemical compound Br.C1=CC(Cl)=CC=C1C1(C(=O)CSC=2NCCCN=2)CCC1 WHKKSMPSUOZMJO-UHFFFAOYSA-N 0.000 description 1
OETSIYDZEGTXEM-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-3-phenylpropan-1-one Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)CCC=2C=CC=CC=2)CCC1 OETSIYDZEGTXEM-UHFFFAOYSA-N 0.000 description 1
KJAJWYWBYJPAMX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]ethanone Chemical compound C=1C=C(Cl)C=CC=1C1(C(=O)C)CCC1 KJAJWYWBYJPAMX-UHFFFAOYSA-N 0.000 description 1
SUHKSQTXXZQEBH-UHFFFAOYSA-N 1-benzothiophen-2-ylmethanol Chemical compound C1=CC=C2SC(CO)=CC2=C1 SUHKSQTXXZQEBH-UHFFFAOYSA-N 0.000 description 1
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
ZLDPQAZOHZSZGX-UHFFFAOYSA-N 1-bromo-3-(3,4-dichlorophenyl)-3-methylbutan-2-one Chemical compound BrCC(=O)C(C)(C)C1=CC=C(Cl)C(Cl)=C1 ZLDPQAZOHZSZGX-UHFFFAOYSA-N 0.000 description 1
CEVMYGZHEJSOHZ-UHFFFAOYSA-N 1-bromo-3-methoxypropane Chemical compound COCCCBr CEVMYGZHEJSOHZ-UHFFFAOYSA-N 0.000 description 1
JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
CGQMSTLTFROKKL-UHFFFAOYSA-N 1-naphthalen-2-ylcyclobutane-1-carbonitrile Chemical compound C=1C=C2C=CC=CC2=CC=1C1(C#N)CCC1 CGQMSTLTFROKKL-UHFFFAOYSA-N 0.000 description 1
MREVQTOCEVYXOO-UHFFFAOYSA-N 2-(1-benzofuran-3-yl)-2,3-dihydroimidazo[2,1-b][1,3]thiazole Chemical class C1=CC=C2C(C3CN4C=CN=C4S3)=COC2=C1 MREVQTOCEVYXOO-UHFFFAOYSA-N 0.000 description 1
FPDPISKSQOVJCV-UHFFFAOYSA-N 2-(1-benzofuran-3-yl)-3,5-dihydro-2h-[1,3]thiazolo[3,2-a]pyrimidine Chemical class C1=CC=C2C(C3CN4CC=CN=C4S3)=COC2=C1 FPDPISKSQOVJCV-UHFFFAOYSA-N 0.000 description 1
SPJJYCYYBXUZCP-UHFFFAOYSA-N 2-(1-benzothiophen-2-yl)acetonitrile Chemical compound C1=CC=C2SC(CC#N)=CC2=C1 SPJJYCYYBXUZCP-UHFFFAOYSA-N 0.000 description 1
XMVHGYKPUBKGIA-UHFFFAOYSA-N 2-(1-benzothiophen-3-yl)-2,3-dihydroimidazo[2,1-b][1,3]thiazole Chemical class C1=CC=C2C(C3CN4C=CN=C4S3)=CSC2=C1 XMVHGYKPUBKGIA-UHFFFAOYSA-N 0.000 description 1
LYYBRLGSNSNFJS-UHFFFAOYSA-N 2-(1-benzothiophen-3-yl)-3,5-dihydro-2h-[1,3]thiazolo[3,2-a]pyrimidine Chemical class C1=CC=C2C(C3CN4CC=CN=C4S3)=CSC2=C1 LYYBRLGSNSNFJS-UHFFFAOYSA-N 0.000 description 1
CIBLYVDBPQODMS-UHFFFAOYSA-N 2-(4-chlorophenyl)-3-[1-(3,4-dichlorophenyl)cyclobutyl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC(Cl)=CC=C1C(S1)=C(C2(CCC2)C=2C=C(Cl)C(Cl)=CC=2)N2C1=NCC2 CIBLYVDBPQODMS-UHFFFAOYSA-N 0.000 description 1
XDGXDWATXRZHMY-UHFFFAOYSA-N 2-(4-chlorophenyl)-3-[1-(3,4-dichlorophenyl)cyclobutyl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1=CC(Cl)=CC=C1C(S1)=C(C2(CCC2)C=2C=C(Cl)C(Cl)=CC=2)N2C1=NCC2 XDGXDWATXRZHMY-UHFFFAOYSA-N 0.000 description 1
VDZGEAGVLWWAGR-UHFFFAOYSA-N 2-benzyl-3-[1-(4-chlorophenyl)cyclobutyl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC(Cl)=CC=C1C1(C=2N3CCN=C3SC=2CC=2C=CC=CC=2)CCC1 VDZGEAGVLWWAGR-UHFFFAOYSA-N 0.000 description 1
RSAUSNRNIIXFGA-UHFFFAOYSA-N 2-bromo-1-[1-(3,4-dichlorophenyl)cyclobutyl]-4-methoxybutan-1-one Chemical compound C=1C=C(Cl)C(Cl)=CC=1C1(C(=O)C(Br)CCOC)CCC1 RSAUSNRNIIXFGA-UHFFFAOYSA-N 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
LPCWDVLDJVZIHA-UHFFFAOYSA-N 2-naphthalen-2-ylacetonitrile Chemical compound C1=CC=CC2=CC(CC#N)=CC=C21 LPCWDVLDJVZIHA-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
DMROAKGZEBHMOQ-UHFFFAOYSA-N 3-(1-naphthalen-2-ylcyclobutyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1CCC1(C=1C=C2C=CC=CC2=CC=1)C1=CSC2=NCCN12 DMROAKGZEBHMOQ-UHFFFAOYSA-N 0.000 description 1
ZZGJVORRXTXUNN-UHFFFAOYSA-N 3-(1-naphthalen-2-ylcyclobutyl)-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidine;hydrobromide Chemical compound Br.C1CCC1(C=1C=C2C=CC=CC2=CC=1)C1=CSC2=NCCCN12 ZZGJVORRXTXUNN-UHFFFAOYSA-N 0.000 description 1
QWPBOFDJGQGXPQ-UHFFFAOYSA-N 3-(1-phenylcyclohexyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.N=1CCN2C=1SC=C2C1(C=2C=CC=CC=2)CCCCC1 QWPBOFDJGQGXPQ-UHFFFAOYSA-N 0.000 description 1
DTBDAFLSBDGPEA-UHFFFAOYSA-N 3-Methylquinoline Natural products C1=CC=CC2=CC(C)=CN=C21 DTBDAFLSBDGPEA-UHFFFAOYSA-N 0.000 description 1
PXUUKOHHLWOYSK-UHFFFAOYSA-N 3-[1-(1-benzothiophen-2-yl)cyclobutyl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1CCC1(C=1SC2=CC=CC=C2C=1)C1=CSC2=NCCN12 PXUUKOHHLWOYSK-UHFFFAOYSA-N 0.000 description 1
VKVAZVQMJARBSJ-UHFFFAOYSA-N 3-[1-(1-benzothiophen-2-yl)cyclobutyl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1CCC1(C=1SC2=CC=CC=C2C=1)C1=CSC2=NCCN12 VKVAZVQMJARBSJ-UHFFFAOYSA-N 0.000 description 1
LXNOMONHDDAQMB-UHFFFAOYSA-N 3-[1-(3,4-dichlorophenyl)cyclobutyl]-2-(2-methoxyethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound N12CCN=C2SC(CCOC)=C1C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 LXNOMONHDDAQMB-UHFFFAOYSA-N 0.000 description 1
PABJRGSHFAXLSJ-UHFFFAOYSA-N 3-[1-(3,4-dichlorophenyl)cyclobutyl]-2-(2-methoxyethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.N12CCN=C2SC(CCOC)=C1C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 PABJRGSHFAXLSJ-UHFFFAOYSA-N 0.000 description 1
TZAIZRDYUIUYQO-UHFFFAOYSA-N 3-[1-(3,4-dichlorophenyl)cyclobutyl]-2-phenyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C=2N3CCN=C3SC=2C=2C=CC=CC=2)CCC1 TZAIZRDYUIUYQO-UHFFFAOYSA-N 0.000 description 1
WGVPRONBDAYHAG-UHFFFAOYSA-N 3-[1-(3,4-dichlorophenyl)cyclobutyl]-2-phenyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1=C(Cl)C(Cl)=CC=C1C1(C=2N3CCN=C3SC=2C=2C=CC=CC=2)CCC1 WGVPRONBDAYHAG-UHFFFAOYSA-N 0.000 description 1
FBKWRYDUNHNREL-UHFFFAOYSA-N 3-[1-(3,4-dichlorophenyl)cyclobutyl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1=C(Cl)C(Cl)=CC=C1C1(C=2N3CCN=C3SC=2)CCC1 FBKWRYDUNHNREL-UHFFFAOYSA-N 0.000 description 1
XZCZSQBPFOWNRW-UHFFFAOYSA-N 3-[1-(3,4-dichlorophenyl)cyclobutyl]-5-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.N12C(C)CN=C2SC=C1C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 XZCZSQBPFOWNRW-UHFFFAOYSA-N 0.000 description 1
OPRWDOSGHNUXJJ-UHFFFAOYSA-N 3-[1-(3,4-dichlorophenyl)cyclobutyl]-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C=2N3CCCN=C3SC=2)CCC1 OPRWDOSGHNUXJJ-UHFFFAOYSA-N 0.000 description 1
CONZWTMHLOMRGU-UHFFFAOYSA-N 3-[1-(3,4-dichlorophenyl)cyclobutyl]-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound N=1C(C)CN2C=1SC=C2C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 CONZWTMHLOMRGU-UHFFFAOYSA-N 0.000 description 1
IFBZTJGMQIDPEE-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)cyclobutyl]-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidine Chemical compound C1=CC(Cl)=CC=C1C1(C=2N3CCCN=C3SC=2)CCC1 IFBZTJGMQIDPEE-UHFFFAOYSA-N 0.000 description 1
KTKZOWDOQMBLGD-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)cyclobutyl]-6,7-dihydro-5h-[1,3]thiazolo[3,2-a]pyrimidine;hydrobromide Chemical compound Br.C1=CC(Cl)=CC=C1C1(C=2N3CCCN=C3SC=2)CCC1 KTKZOWDOQMBLGD-UHFFFAOYSA-N 0.000 description 1
SBYSIWCFLVLEKO-UHFFFAOYSA-N 3-[1-(4-methylsulfanylphenyl)cyclobutyl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C1=CC(SC)=CC=C1C1(C=2N3CCN=C3SC=2)CCC1 SBYSIWCFLVLEKO-UHFFFAOYSA-N 0.000 description 1
FNXRBDGWNKSKTH-UHFFFAOYSA-N 3-[2-(3,4-dichlorophenyl)propan-2-yl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C=1SC2=NCCN2C=1C(C)(C)C1=CC=C(Cl)C(Cl)=C1 FNXRBDGWNKSKTH-UHFFFAOYSA-N 0.000 description 1
LJTWISIVSKTUGE-UHFFFAOYSA-N 3-[2-(4-chlorophenyl)propan-2-yl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound C=1SC2=NCCN2C=1C(C)(C)C1=CC=C(Cl)C=C1 LJTWISIVSKTUGE-UHFFFAOYSA-N 0.000 description 1
LKNRWGJOUAEIEL-UHFFFAOYSA-N 3-[2-(4-chlorophenyl)propan-2-yl]-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.C=1SC2=NCCN2C=1C(C)(C)C1=CC=C(Cl)C=C1 LKNRWGJOUAEIEL-UHFFFAOYSA-N 0.000 description 1
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
VBEGFQSSVDGTNM-UHFFFAOYSA-N 4-(1-naphthalen-2-ylcyclobutyl)-n,3-bis(pyridin-3-ylmethyl)-1,3-thiazol-2-imine Chemical compound C=1C=CN=CC=1CN=C1SC=C(C2(CCC2)C=2C=C3C=CC=CC3=CC=2)N1CC1=CC=CN=C1 VBEGFQSSVDGTNM-UHFFFAOYSA-N 0.000 description 1
FGRYHKLSQLYGPT-UHFFFAOYSA-N 4-(1-naphthalen-2-ylcyclobutyl)-n,3-bis(pyridin-3-ylmethyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C=1C=CN=CC=1CN=C1SC=C(C2(CCC2)C=2C=C3C=CC=CC3=CC=2)N1CC1=CC=CN=C1 FGRYHKLSQLYGPT-UHFFFAOYSA-N 0.000 description 1
WGBOGKTXQZWLLF-UHFFFAOYSA-N 4-(1-naphthalen-2-ylcyclobutyl)-n,3-diphenyl-1,3-thiazol-2-imine Chemical compound C1CCC1(C=1C=C2C=CC=CC2=CC=1)C(N1C=2C=CC=CC=2)=CSC1=NC1=CC=CC=C1 WGBOGKTXQZWLLF-UHFFFAOYSA-N 0.000 description 1
CDWVJCIZYWAEEA-UHFFFAOYSA-N 4-(1-naphthalen-2-ylcyclobutyl)-n,3-dipropyl-1,3-thiazol-2-imine Chemical compound CCCN1C(=NCCC)SC=C1C1(C=2C=C3C=CC=CC3=CC=2)CCC1 CDWVJCIZYWAEEA-UHFFFAOYSA-N 0.000 description 1
FMUNXMHHOQRRKX-UHFFFAOYSA-N 4-(1-naphthalen-2-ylcyclobutyl)-n,3-dipropyl-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.CCCN1C(=NCCC)SC=C1C1(C=2C=C3C=CC=CC3=CC=2)CCC1 FMUNXMHHOQRRKX-UHFFFAOYSA-N 0.000 description 1
NYANKRDXCOVJIK-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis(2-methylpropyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.CC(C)CN1C(=NCC(C)C)SC=C1C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 NYANKRDXCOVJIK-UHFFFAOYSA-N 0.000 description 1
JAXZUOFXCWTJMZ-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis(2-phenylethyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C1=C(Cl)C(Cl)=CC=C1C1(C=2N(C(=NCCC=3C=CC=CC=3)SC=2)CCC=2C=CC=CC=2)CCC1 JAXZUOFXCWTJMZ-UHFFFAOYSA-N 0.000 description 1
KEPZVTGYXLHQBM-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis(4-ethoxyphenyl)-1,3-thiazol-2-imine Chemical compound C1=CC(OCC)=CC=C1N=C1N(C=2C=CC(OCC)=CC=2)C(C2(CCC2)C=2C=C(Cl)C(Cl)=CC=2)=CS1 KEPZVTGYXLHQBM-UHFFFAOYSA-N 0.000 description 1
XQBUATMLWOHQAA-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis(4-ethoxyphenyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C1=CC(OCC)=CC=C1N=C1N(C=2C=CC(OCC)=CC=2)C(C2(CCC2)C=2C=C(Cl)C(Cl)=CC=2)=CS1 XQBUATMLWOHQAA-UHFFFAOYSA-N 0.000 description 1
OUYLNBSIGYVHHB-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis(4-methylphenyl)-1,3-thiazol-2-imine Chemical compound C1=CC(C)=CC=C1N=C1N(C=2C=CC(C)=CC=2)C(C2(CCC2)C=2C=C(Cl)C(Cl)=CC=2)=CS1 OUYLNBSIGYVHHB-UHFFFAOYSA-N 0.000 description 1
HVBWVTKTCNXYRT-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis(pyridin-3-ylmethyl)-1,3-thiazol-2-imine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C=2N(C(=NCC=3C=NC=CC=3)SC=2)CC=2C=NC=CC=2)CCC1 HVBWVTKTCNXYRT-UHFFFAOYSA-N 0.000 description 1
UAXQQBJAQRRHLQ-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis(pyridin-3-ylmethyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C1=C(Cl)C(Cl)=CC=C1C1(C=2N(C(=NCC=3C=NC=CC=3)SC=2)CC=2C=NC=CC=2)CCC1 UAXQQBJAQRRHLQ-UHFFFAOYSA-N 0.000 description 1
WPDGHUJVBQXHGS-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis[(4-fluorophenyl)methyl]-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C1=CC(F)=CC=C1CN=C1N(CC=2C=CC(F)=CC=2)C(C2(CCC2)C=2C=C(Cl)C(Cl)=CC=2)=CS1 WPDGHUJVBQXHGS-UHFFFAOYSA-N 0.000 description 1
CETRTCKEHXTWTO-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-imine Chemical compound FC(F)(F)C1=CC=CC(N=C2N(C(=CS2)C2(CCC2)C=2C=C(Cl)C(Cl)=CC=2)C=2C=C(C=CC=2)C(F)(F)F)=C1 CETRTCKEHXTWTO-UHFFFAOYSA-N 0.000 description 1
LILDIFJTSLDAIV-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-bis[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.FC(F)(F)C1=CC=CC(N=C2N(C(=CS2)C2(CCC2)C=2C=C(Cl)C(Cl)=CC=2)C=2C=C(C=CC=2)C(F)(F)F)=C1 LILDIFJTSLDAIV-UHFFFAOYSA-N 0.000 description 1
MWNINNMHDQJBCZ-UHFFFAOYSA-N 4-[1-(3,4-dichlorophenyl)cyclobutyl]-n,3-diethyl-1,3-thiazol-2-imine Chemical compound CCN1C(=NCC)SC=C1C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 MWNINNMHDQJBCZ-UHFFFAOYSA-N 0.000 description 1
YMGYOLFMBMYUFX-UHFFFAOYSA-N 4-[1-(4-bromophenyl)cyclobutyl]-n,3-dibutyl-1,3-thiazol-2-imine Chemical compound CCCCN1C(=NCCCC)SC=C1C1(C=2C=CC(Br)=CC=2)CCC1 YMGYOLFMBMYUFX-UHFFFAOYSA-N 0.000 description 1
PXKXCQKMJZYMHQ-UHFFFAOYSA-N 4-[1-(4-chlorophenyl)cyclobutyl]-n,3-bis[2-(3,4-dimethoxyphenyl)ethyl]-1,3-thiazol-2-imine Chemical compound C1=C(OC)C(OC)=CC=C1CCN=C1N(CCC=2C=C(OC)C(OC)=CC=2)C(C2(CCC2)C=2C=CC(Cl)=CC=2)=CS1 PXKXCQKMJZYMHQ-UHFFFAOYSA-N 0.000 description 1
OVTFBJLFKZKMSA-UHFFFAOYSA-N 4-[1-(4-chlorophenyl)cyclopentyl]-n,3-bis[2-(3,4-dimethoxyphenyl)ethyl]-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C1=C(OC)C(OC)=CC=C1CCN=C1N(CCC=2C=C(OC)C(OC)=CC=2)C(C2(CCCC2)C=2C=CC(Cl)=CC=2)=CS1 OVTFBJLFKZKMSA-UHFFFAOYSA-N 0.000 description 1
ZRMAOFSYSYAOHQ-UHFFFAOYSA-N 4-methoxybutanal Chemical compound COCCCC=O ZRMAOFSYSYAOHQ-UHFFFAOYSA-N 0.000 description 1
NMQWMGLBFCJGKK-UHFFFAOYSA-N 5-methyl-3-(1-naphthalen-2-ylcyclobutyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole Chemical compound N12C(C)CN=C2SC=C1C1(C=2C=C3C=CC=CC3=CC=2)CCC1 NMQWMGLBFCJGKK-UHFFFAOYSA-N 0.000 description 1
ZOIUNHORONFHON-UHFFFAOYSA-N 6-methyl-3-(1-naphthalen-2-ylcyclobutyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrobromide Chemical compound Br.N=1C(C)CN2C=1SC=C2C1(C=2C=C3C=CC=CC3=CC=2)CCC1 ZOIUNHORONFHON-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
240000002470 Amphicarpaea bracteata Species 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
JPSGDXKGWNVECC-UHFFFAOYSA-N Br.COC=1C=C(C=CC1OC)CCN=C1SC=CN1 Chemical compound Br.COC=1C=C(C=CC1OC)CCN=C1SC=CN1 JPSGDXKGWNVECC-UHFFFAOYSA-N 0.000 description 1
SGLKGPMHQNJFJT-UHFFFAOYSA-N C1(=CC=CC=C1)C1(CCCCC1)C1SC=CN1 Chemical compound C1(=CC=CC=C1)C1(CCCCC1)C1SC=CN1 SGLKGPMHQNJFJT-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241001024304 Mino Species 0.000 description 1
LYAVXWPXKIFHBU-UHFFFAOYSA-N N-{2-[(1,2-diphenylhydrazinyl)carbonyl]-2-hydroxyhexanoyl}-6-aminohexanoic acid Chemical compound C=1C=CC=CC=1N(C(=O)C(O)(C(=O)NCCCCCC(O)=O)CCCC)NC1=CC=CC=C1 LYAVXWPXKIFHBU-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
NRAFPLGJPPJUNB-UHFFFAOYSA-M [Cl-].[Mg+]CC1=CC=CC=C1 Chemical compound [Cl-].[Mg+]CC1=CC=CC=C1 NRAFPLGJPPJUNB-UHFFFAOYSA-M 0.000 description 1
SNIYGPDAYLBEMK-UHFFFAOYSA-M [I-].[Mg+]C1=CC=CC=C1 Chemical compound [I-].[Mg+]C1=CC=CC=C1 SNIYGPDAYLBEMK-UHFFFAOYSA-M 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000012042 active reagent Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
229960000911 benserazide Drugs 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 1
229960004205 carbidopa Drugs 0.000 description 1
MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical class BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000003543 catechol methyltransferase inhibitor Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
GFBLFDSCAKHHGX-UHFFFAOYSA-N cyclobutanecarbonitrile Chemical compound N#CC1CCC1 GFBLFDSCAKHHGX-UHFFFAOYSA-N 0.000 description 1
229960002944 cyclofenil Drugs 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
239000003954 decarboxylase inhibitor Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
230000029087 digestion Effects 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
229960003337 entacapone Drugs 0.000 description 1
JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
239000004009 herbicide Substances 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
150000002462 imidazolines Chemical class 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
YADSQVVJGJHEMZ-UHFFFAOYSA-M magnesium;1-methoxypropane;bromide Chemical compound [Mg+2].[Br-].COCC[CH2-] YADSQVVJGJHEMZ-UHFFFAOYSA-M 0.000 description 1
SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
QOCUIZBWBKTPRD-UHFFFAOYSA-N n,3-bis(2-methylpropyl)-4-(1-naphthalen-2-ylcyclobutyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.CC(C)CN1C(=NCC(C)C)SC=C1C1(C=2C=C3C=CC=CC3=CC=2)CCC1 QOCUIZBWBKTPRD-UHFFFAOYSA-N 0.000 description 1
VHSVEPUPZMGYIQ-UHFFFAOYSA-N n,3-bis(4-methylphenyl)-4-(1-naphthalen-2-ylcyclobutyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C1=CC(C)=CC=C1N=C1N(C=2C=CC(C)=CC=2)C(C2(CCC2)C=2C=C3C=CC=CC3=CC=2)=CS1 VHSVEPUPZMGYIQ-UHFFFAOYSA-N 0.000 description 1
TWAZLLDWGFWHMR-UHFFFAOYSA-N n,3-bis(cyclopropylmethyl)-4-(1-naphthalen-2-ylcyclobutyl)-1,3-thiazol-2-imine Chemical compound C1CC1CN=C1SC=C(C2(CCC2)C=2C=C3C=CC=CC3=CC=2)N1CC1CC1 TWAZLLDWGFWHMR-UHFFFAOYSA-N 0.000 description 1
VQURSJYFSGADBL-UHFFFAOYSA-N n,3-bis(cyclopropylmethyl)-4-[1-(3,4-dichlorophenyl)cyclobutyl]-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C1=C(Cl)C(Cl)=CC=C1C1(C=2N(C(=NCC3CC3)SC=2)CC2CC2)CCC1 VQURSJYFSGADBL-UHFFFAOYSA-N 0.000 description 1
UFUJWWGRVKVDGT-UHFFFAOYSA-N n,3-bis[(4-fluorophenyl)methyl]-4-(1-naphthalen-2-ylcyclobutyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C1=CC(F)=CC=C1CN=C1N(CC=2C=CC(F)=CC=2)C(C2(CCC2)C=2C=C3C=CC=CC3=CC=2)=CS1 UFUJWWGRVKVDGT-UHFFFAOYSA-N 0.000 description 1
ZGLNSGJBKZMGAZ-UHFFFAOYSA-N n,3-bis[2-(3,4-dimethoxyphenyl)ethyl]-4-(1-phenylcyclohexyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C1=C(OC)C(OC)=CC=C1CCN=C1N(CCC=2C=C(OC)C(OC)=CC=2)C(C2(CCCCC2)C=2C=CC=CC=2)=CS1 ZGLNSGJBKZMGAZ-UHFFFAOYSA-N 0.000 description 1
HBTFJAQDPFOROU-UHFFFAOYSA-N n,3-dibutyl-4-(1-phenylcyclohexyl)-1,3-thiazol-2-imine Chemical compound CCCCN1C(=NCCCC)SC=C1C1(C=2C=CC=CC=2)CCCCC1 HBTFJAQDPFOROU-UHFFFAOYSA-N 0.000 description 1
URRBCIDKRWITTM-UHFFFAOYSA-N n,3-dibutyl-4-(1-phenylcyclohexyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.CCCCN1C(=NCCCC)SC=C1C1(C=2C=CC=CC=2)CCCCC1 URRBCIDKRWITTM-UHFFFAOYSA-N 0.000 description 1
IAJLHNUYVOHYLL-UHFFFAOYSA-N n,3-dibutyl-4-[1-(3,4-dichlorophenyl)cyclobutyl]-1,3-thiazol-2-imine Chemical compound CCCCN1C(=NCCCC)SC=C1C1(C=2C=C(Cl)C(Cl)=CC=2)CCC1 IAJLHNUYVOHYLL-UHFFFAOYSA-N 0.000 description 1
KQRVGGHUMAMWJV-UHFFFAOYSA-N n,3-dibutyl-4-[1-(4-chlorophenyl)cyclobutyl]-1,3-thiazol-2-imine Chemical compound CCCCN1C(=NCCCC)SC=C1C1(C=2C=CC(Cl)=CC=2)CCC1 KQRVGGHUMAMWJV-UHFFFAOYSA-N 0.000 description 1
IHUJGAJDXFZADD-UHFFFAOYSA-N n,3-dibutyl-4-[1-(4-chlorophenyl)cyclobutyl]-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.CCCCN1C(=NCCCC)SC=C1C1(C=2C=CC(Cl)=CC=2)CCC1 IHUJGAJDXFZADD-UHFFFAOYSA-N 0.000 description 1
AEBTXXPVYTZLBI-UHFFFAOYSA-N n,3-dibutyl-4-[1-(4-chlorophenyl)cyclopentyl]-1,3-thiazol-2-imine Chemical compound CCCCN1C(=NCCCC)SC=C1C1(C=2C=CC(Cl)=CC=2)CCCC1 AEBTXXPVYTZLBI-UHFFFAOYSA-N 0.000 description 1
ZCGIZHQQBFKLSO-UHFFFAOYSA-N n,3-dibutyl-4-[1-(4-chlorophenyl)cyclopentyl]-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.CCCCN1C(=NCCCC)SC=C1C1(C=2C=CC(Cl)=CC=2)CCCC1 ZCGIZHQQBFKLSO-UHFFFAOYSA-N 0.000 description 1
XOOLQOKXLAKKLL-UHFFFAOYSA-N n,3-dibutyl-4-[1-(4-methylsulfanylphenyl)cyclobutyl]-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.CCCCN1C(=NCCCC)SC=C1C1(C=2C=CC(SC)=CC=2)CCC1 XOOLQOKXLAKKLL-UHFFFAOYSA-N 0.000 description 1
MQSMRDHAQGKZPW-UHFFFAOYSA-N n,3-dibutyl-4-[1-(4-phenoxyphenyl)cyclobutyl]-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.CCCCN1C(=NCCCC)SC=C1C1(C=2C=CC(OC=3C=CC=CC=3)=CC=2)CCC1 MQSMRDHAQGKZPW-UHFFFAOYSA-N 0.000 description 1
SMRBGFCSADEWLJ-UHFFFAOYSA-N n,3-dicyclopentyl-4-(1-naphthalen-2-ylcyclobutyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.C1CCC1(C=1C=C2C=CC=CC2=CC=1)C(N1C2CCCC2)=CSC1=NC1CCCC1 SMRBGFCSADEWLJ-UHFFFAOYSA-N 0.000 description 1
VYSJEISAAJONPI-UHFFFAOYSA-N n,3-diethyl-4-(1-naphthalen-2-ylcyclobutyl)-1,3-thiazol-2-imine;hydrobromide Chemical compound Br.CCN1C(=NCC)SC=C1C1(C=2C=C3C=CC=CC3=CC=2)CCC1 VYSJEISAAJONPI-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000019809 paraffin wax Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000021400 peanut butter Nutrition 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
229960003089 pramipexole Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
BATMYWDOUUWCJE-UHFFFAOYSA-N pyrimidin-1-ium;bromide Chemical compound Br.C1=CN=CN=C1 BATMYWDOUUWCJE-UHFFFAOYSA-N 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
238000002791 soaking Methods 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960004603 tolcapone Drugs 0.000 description 1
MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Hematology (AREA)
Psychology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Thiazole And Isothizaole Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

BG103754A 1997-03-15 1999-09-24 Заместени 4-арилметилен-2-имино-2,3-дихидротиазоли, техни производни и използването им във фармацията BG103754A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9705428.2A GB9705428D0 (en)	1997-03-15	1997-03-15	Therapeutic agents
PCT/EP1998/001358 WO1998041528A1 (en)	1997-03-15	1998-03-09	Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use

Publications (1)

Publication Number	Publication Date
BG103754A true BG103754A (bg)	2000-06-30

Family

ID=10809320

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103754A BG103754A (bg)	1997-03-15	1999-09-24	Заместени 4-арилметилен-2-имино-2,3-дихидротиазоли, техни производни и използването им във фармацията

Country Status (22)

Country	Link
US (1)	US6187802B1 (de)
EP (1)	EP0970090B1 (de)
JP (1)	JP2001515501A (de)
KR (1)	KR20000076190A (de)
CN (1)	CN1255136A (de)
AT (1)	ATE218573T1 (de)
AU (1)	AU6728898A (de)
BG (1)	BG103754A (de)
BR (1)	BR9808254A (de)
CA (1)	CA2283438A1 (de)
DE (1)	DE69805781D1 (de)
GB (1)	GB9705428D0 (de)
HU (1)	HUP0001508A3 (de)
ID (1)	ID22636A (de)
IL (1)	IL131515A0 (de)
NO (1)	NO994452L (de)
NZ (1)	NZ337378A (de)
PL (1)	PL335696A1 (de)
SK (1)	SK122099A3 (de)
TR (1)	TR199902291T2 (de)
WO (1)	WO1998041528A1 (de)
ZA (1)	ZA982134B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19856965A1 (de) *	1998-12-10	2000-06-15	Bayer Ag	Substituierte 2-Imino-thiazoline
AU3895400A (en)	1999-03-19	2000-10-09	Knoll Pharmaceutical Company	Control of metabolism
WO2000056321A1 (en)	1999-03-19	2000-09-28	Knoll Pharmaceutical Company	Treatment of hyperactivity disorders
WO2000056308A1 (en)	1999-03-19	2000-09-28	Knoll Pharmaceutical Company	Prevention of cardiovascular disease
WO2000056319A1 (en)	1999-03-19	2000-09-28	Knoll Pharmaceutical Company	Treatment of orthostatic hypotension
US6803387B1 (en)	1999-03-19	2004-10-12	Abbott Gmbh & Co. Kg	Treatment of neuropathic pain or fibromyalgia
US6376551B1 (en)	1999-03-19	2002-04-23	Knoll Pharmaceutical Company	Treatment of chronic fatigue syndrome
WO2000056309A1 (en)	1999-03-19	2000-09-28	Knoll Pharmaceutical Company	Method of treating sexual dysfunction
EP1162964A1 (de)	1999-03-19	2001-12-19	Knoll GmbH	Behandlung der pulmonalen hypertonie
GB9911881D0 (en) *	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
GB9911863D0 (en) *	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
FR2796643B1 (fr) *	1999-07-22	2005-04-29	Sod Conseils Rech Applic	Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0005789D0 (en) *	2000-03-11	2000-05-03	Knoll Ag	Therapeutic agents
AU2002314744A1 (en)	2001-04-17	2002-10-28	Sepracor, Inc.	Thiazole and other heterocyclic ligands and use thereof
US20060281797A1 (en) *	2001-12-11	2006-12-14	University Of Virginia Patent Foundation	Neurorestoration with R(+) Pramipexole
ES2432527T3 (es) *	2001-12-11	2013-12-04	University Of Virginia Patent Foundation	Uso de pramipexol para tratar la esclerosis lateral amiotrófica
US6743797B2 (en) *	2002-02-22	2004-06-01	Chantest, Inc.	Methods for treating cardiac arrhythmia
US7211407B2 (en) *	2003-07-15	2007-05-01	Chan Test, Inc.	High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
US20050054010A1 (en) *	2003-07-15	2005-03-10	Brown Arthur M.	High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
US20050208595A1 (en) *	2004-03-19	2005-09-22	Brown Arthur M	High throughput assay systems and methods for identifying agents that alter expression of cellular proteins
ATE444750T1 (de) *	2005-08-15	2009-10-15	Univ Virginia	Neurorestauration mit r(+) pramipexol
BRPI0706365A2 (pt) *	2006-01-06	2011-03-22	Sepracor Inc	Cicloalquilaminas como inibidores da recaptação de monoamina
KR100752757B1 (ko) *	2006-04-05	2007-08-29	한국과학기술연구원	2-페닐이미노-1,3-티아졸린을 포함하는 미백 조성물
US20070259930A1 (en) *	2006-04-10	2007-11-08	Knopp Neurosciences, Inc.	Compositions and methods of using r(+) pramipexole
US8518926B2 (en) *	2006-04-10	2013-08-27	Knopp Neurosciences, Inc.	Compositions and methods of using (R)-pramipexole
ATE537826T1 (de)	2006-05-16	2012-01-15	Knopp Neurosciences Inc	Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
US8524695B2 (en) *	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja)	2007-03-14	2010-06-24	ノップニューロサイエンシーズ、インク．	キラル精製置換ベンゾチアゾールジアミンの合成
US20110190356A1 (en) *	2008-08-19	2011-08-04	Knopp Neurosciences Inc.	Compositions and Methods of Using (R)- Pramipexole
KR101049935B1 (ko) *	2008-12-03	2011-07-15	한국과학기술연구원	신규한 티아졸린계 화합물 및 이를 포함하는 ｔ-형 칼슘 채널 저해제
AU2010262970A1 (en) *	2009-06-19	2012-01-12	Knopp Neurosciences, Inc.	Compositions and methods for treating amyotrophic lateral sclerosis
WO2013096816A1 (en)	2011-12-22	2013-06-27	Biogen Idec Ma Inc.	Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en)	2013-02-28	2017-05-30	Knopp Biosciences Llc	Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en)	2013-07-12	2016-10-18	Knopp Biosciences Llc	Compositions and methods for treating conditions related to increased eosinophils
PL3019167T3 (pl)	2013-07-12	2021-06-14	Knopp Biosciences Llc	Leczenie podwyższonych poziomów eozynofili i/lub bazofili
DK3033081T3 (da)	2013-08-13	2021-05-31	Knopp Biosciences Llc	Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
EP3038467B1 (de)	2013-08-13	2020-07-29	Knopp Biosciences LLC	Zusammensetzungen und verfahren zur behandlung von plasmazellenerkrankungen und prolymphozytischen b-zellen-erkrankungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4347248A (en)	1981-03-23	1982-08-31	American Cyanamid Company	2,3-Disubstituted-thiazolo[3,2-a]pyrimidines
US5232921A (en) *	1987-03-12	1993-08-03	Sanofi	Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
FR2612187B1 (fr) *	1987-03-12	1989-07-21	Sanofi Sa	Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant
US5463069A (en)	1992-12-04	1995-10-31	Sumitomo Chemical Company, Limited	Process of producing 2-iminothiazoline derivatives and process of producing their intermediates
CN1113242A (zh) *	1994-04-04	1995-12-13	住友化学工业株式会社	亚氨基噻唑啉衍生物及含有它们作为活性成分的除草剂
GB9513467D0 (en)	1995-07-01	1995-09-06	Knoll Ag	Therapeutic agents

1997
- 1997-03-15 GB GBGB9705428.2A patent/GB9705428D0/en active Pending
1998
- 1998-03-09 BR BR9808254-0A patent/BR9808254A/pt not_active IP Right Cessation
- 1998-03-09 SK SK1220-99A patent/SK122099A3/sk unknown
- 1998-03-09 IL IL13151598A patent/IL131515A0/xx unknown
- 1998-03-09 JP JP54009198A patent/JP2001515501A/ja active Pending
- 1998-03-09 PL PL98335696A patent/PL335696A1/xx unknown
- 1998-03-09 ID IDW991023A patent/ID22636A/id unknown
- 1998-03-09 CA CA002283438A patent/CA2283438A1/en not_active Abandoned
- 1998-03-09 EP EP98912459A patent/EP0970090B1/de not_active Expired - Lifetime
- 1998-03-09 KR KR1019997008284A patent/KR20000076190A/ko not_active Withdrawn
- 1998-03-09 AU AU67288/98A patent/AU6728898A/en not_active Abandoned
- 1998-03-09 CN CN98804891A patent/CN1255136A/zh active Pending
- 1998-03-09 NZ NZ337378A patent/NZ337378A/xx unknown
- 1998-03-09 TR TR1999/02291T patent/TR199902291T2/xx unknown
- 1998-03-09 AT AT98912459T patent/ATE218573T1/de not_active IP Right Cessation
- 1998-03-09 HU HU0001508A patent/HUP0001508A3/hu unknown
- 1998-03-09 US US09/380,967 patent/US6187802B1/en not_active Expired - Fee Related
- 1998-03-09 WO PCT/EP1998/001358 patent/WO1998041528A1/en not_active Ceased
- 1998-03-09 DE DE69805781T patent/DE69805781D1/de not_active Expired - Lifetime
- 1998-03-13 ZA ZA9802134A patent/ZA982134B/xx unknown
1999
- 1999-09-14 NO NO994452A patent/NO994452L/no unknown
- 1999-09-24 BG BG103754A patent/BG103754A/bg unknown

Also Published As

Publication number	Publication date
AU6728898A (en)	1998-10-12
BR9808254A (pt)	2000-05-16
GB9705428D0 (en)	1997-04-30
SK122099A3 (en)	2000-05-16
WO1998041528A1 (en)	1998-09-24
CA2283438A1 (en)	1998-09-24
NO994452D0 (no)	1999-09-14
EP0970090A1 (de)	2000-01-12
CN1255136A (zh)	2000-05-31
ID22636A (id)	1999-12-02
ATE218573T1 (de)	2002-06-15
TR199902291T2 (xx)	1999-12-21
EP0970090B1 (de)	2002-06-05
NO994452L (no)	1999-09-14
KR20000076190A (ko)	2000-12-26
PL335696A1 (en)	2000-05-08
NZ337378A (en)	2001-01-26
US6187802B1 (en)	2001-02-13
HUP0001508A3 (en)	2003-01-28
HUP0001508A2 (hu)	2001-01-29
ZA982134B (en)	1999-09-13
IL131515A0 (en)	2001-01-28
JP2001515501A (ja)	2001-09-18
DE69805781D1 (de)	2002-07-11

Publication	Publication Date	Title
BG103754A (bg)	2000-06-30	Заместени 4-арилметилен-2-имино-2,3-дихидротиазоли, техни производни и използването им във фармацията
EP1891042B1 (de)	2013-10-02	2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre therapeutische anwendung auf das zentrale nervensystem
SK16852001A3 (sk)	2002-05-09	Tiazolové deriváty a farmaceutické kompozície ich obsahujúce
KR100305071B1 (ko)	2001-12-12	벤질-락탐유도체및/또는벤질리덴-락탐유도체,이들의제조방법및이들의세로토닌1에이및/또는세로토닌1디수용체의선택적인길항제및/또는작용제로서의용도
SK16842001A3 (sk)	2002-04-04	Substituované imidazotiazoly ako antidepresívne prostriedky
AU603776B2 (en)	1990-11-29	Isothiazolone derivatives
KR100417506B1 (ko)	2004-02-05	항우울 치료를 위한 5ｈｔ1 길항제
AU631982B2 (en)	1992-12-10	5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers
US5869492A (en)	1999-02-09	Condensed thiazole derivatives, having 5-HT receptor affinity
HUP0000489A2 (hu)	2000-12-28	5-HT-Receptor affinitású szulfonamidszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
CZ9903260A3 (cs)	2000-11-15	Terapeutická činidla
MXPA97009509A (en)	1998-10-15	Therapeutic agents